TCR² Therapeutics to Present at the H.C. Wainwright BioConnect Conference
TCR² Therapeutics (Nasdaq: TCRR), a clinical-stage cell therapy company, announced that CEO Garry Menzel will present an update on the company's progress at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TCR² Therapeutics (Nasdaq: TCRR), a clinical-stage cell therapy company, announced that CEO Garry Menzel will present an update on the company's progress at the H.C. Wainwright BioConnect Conference on January 10, 2022, at 7:00 AM ET. The presentation will take place on a virtual platform, and a live webcast will be available on the company's Investors page. An archived replay will be accessible for at least 30 days following the event. TCR² focuses on developing novel T cell therapies for cancer patients targeting solid tumors.
Details
News Market Reaction – TCRR
The recorded move for TCRR in the trading session of this news was -7.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that Garry Menzel, President and Chief Executive Officer of TCR² Therapeutics, will present an update on Company progress at the H.C. Wainwright BioConnect Conference on Monday, January 10th at 7:00AM E.T. using a virtual platform.
A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.
About TCR² Therapeutics
TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.
Investor and Media Contacts:
TCR² Therapeutics
Carl Mauch
Director, Investor Relations and Corporate Communications
(617) 949-5667
carl.mauch@tcr2.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.